Last December, President Donald Trump convened a meeting of pharmaceutical executives with the goal of getting them to lower the cost of prescription drugs. A few weeks later, one patient battling lung cancer checked into a California clinic for an infusion of Merck & Co.'s blockbuster cancer drug, Keytruda. When the bill arrived, the clinic's charge for a 400 mg dose dominated the page: It was just over $162,000. While Brown only owed about $2,000 herself, the six-figure charges show how quickly prices for cutting-edge medical treatments can balloon in the U.S. health care system. USA TODAY joined the International Consortium of Investigative Journalists in their year-long, reporting effort looking into rising healthcare costs around the world. USA TODAY Health Reporter Ken Alltucker joined The Excerpt to share his insights.

Let us know what you think of this episode by sending an email to podcasts@usatoday.com.

Episode transcript available here.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

The blockbuster cancer drug Keytruda can cost over $150,000